Pediatric medulloblastoma express immune checkpoint B7-H3

S Li; G C Poolen; L C van Vliet; J G Schipper; R Broekhuizen; M Monnikhof; W Van Hecke; J F Vermeulen; N Bovenschen

doi:10.1007/s12094-021-02762-y

Pediatric medulloblastoma express immune checkpoint B7-H3

S Li
, G C Poolen
, L C van Vliet
, J G Schipper
, R Broekhuizen
, M Monnikhof
, W Van Hecke
, J F Vermeulen
, N Bovenschen

Research output: Contribution to journal › Article › Academic › peer-review

5 Downloads (Pure)

Abstract

PURPOSE: Medulloblastomas (MB) are highly malignant brain tumors that predominantly occur in young infants. Immunotherapy to boost the immune system is emerging as a novel promising approach, but is often hampered by inhibitory immune checkpoints. In the present study, we have studied immune checkpoint B7-H3 expression in a tissue cohort of human pediatric MB.

METHODS: Expression of B7-H3 was detected by immunohistochemistry and classified via B7-H3 staining intensity and percentage of B7-H3 positive tumor cells. Subsequently, B7-H3 protein expression was distinguished in MB molecular subtypes and correlated to immune cell infiltrates, patient characteristics, and survival.

RESULTS: B7-H3 protein expression was found in 23 out of 24 (96%) human pediatric MB cases and in 17 out of 24 (71%) MB cases > 25% of tumor cells had any level of B7-H3 expression. B7-H3 protein expression was more frequent on Group-4 MB as compared with other molecular subtypes (p = 0.02). Tumors with high B7-H3 expression showed less influx of γδT cells (p = 0.002) and CD3+ T cells (p = 0.041).

CONCLUSION: Immune checkpoint B7-H3 is differentially expressed by the large majority of pediatric MB. This further warrants the development of novel B7-H3-directed (immuno)therapeutic methods for children with incurable, metastatic, or chemo-resistant MB.

Original language	English
Pages (from-to)	1204-1208
Number of pages	5
Journal	Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Volume	24
Issue number	6
Early online date	5 Jan 2022
DOIs	https://doi.org/10.1007/s12094-021-02762-y
Publication status	Published - Jun 2022

Keywords

Brain cancer
Immune checkpoint
Immunotherapy
Pediatric medulloblastoma

Access to Document

10.1007/s12094-021-02762-yLicence: CC BY

Li2022_Article_PediatricMedulloblastomaExpresFinal published version, 773 KBLicence: CC BY

Cite this

Li, S., Poolen, G. C., van Vliet, L. C., Schipper, J. G., Broekhuizen, R., Monnikhof, M., Van Hecke, W., Vermeulen, J. F., & Bovenschen, N. (2022). Pediatric medulloblastoma express immune checkpoint B7-H3. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 24(6), 1204-1208. https://doi.org/10.1007/s12094-021-02762-y

@article{d71dfd67f0ef4e7ca13cd67b9a10aa51,

title = "Pediatric medulloblastoma express immune checkpoint B7-H3",

abstract = "PURPOSE: Medulloblastomas (MB) are highly malignant brain tumors that predominantly occur in young infants. Immunotherapy to boost the immune system is emerging as a novel promising approach, but is often hampered by inhibitory immune checkpoints. In the present study, we have studied immune checkpoint B7-H3 expression in a tissue cohort of human pediatric MB.METHODS: Expression of B7-H3 was detected by immunohistochemistry and classified via B7-H3 staining intensity and percentage of B7-H3 positive tumor cells. Subsequently, B7-H3 protein expression was distinguished in MB molecular subtypes and correlated to immune cell infiltrates, patient characteristics, and survival.RESULTS: B7-H3 protein expression was found in 23 out of 24 (96\%) human pediatric MB cases and in 17 out of 24 (71\%) MB cases > 25\% of tumor cells had any level of B7-H3 expression. B7-H3 protein expression was more frequent on Group-4 MB as compared with other molecular subtypes (p = 0.02). Tumors with high B7-H3 expression showed less influx of γδT cells (p = 0.002) and CD3+ T cells (p = 0.041).CONCLUSION: Immune checkpoint B7-H3 is differentially expressed by the large majority of pediatric MB. This further warrants the development of novel B7-H3-directed (immuno)therapeutic methods for children with incurable, metastatic, or chemo-resistant MB.",

keywords = "Brain cancer, Immune checkpoint, Immunotherapy, Pediatric medulloblastoma",

author = "S Li and Poolen, \{G C\} and \{van Vliet\}, \{L C\} and Schipper, \{J G\} and R Broekhuizen and M Monnikhof and \{Van Hecke\}, W and Vermeulen, \{J F\} and N Bovenschen",

note = "Funding Information: This work was supported by a research grants from Cancer Foundation Koppie-Au and Foundation Team Doelbewust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jun,

doi = "10.1007/s12094-021-02762-y",

language = "English",

volume = "24",

pages = "1204--1208",

journal = "Clinical \& translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico",

issn = "1699-048X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

Li, S, Poolen, GC, van Vliet, LC, Schipper, JG, Broekhuizen, R, Monnikhof, M, Van Hecke, W, Vermeulen, JF & Bovenschen, N 2022, 'Pediatric medulloblastoma express immune checkpoint B7-H3', Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 24, no. 6, pp. 1204-1208. https://doi.org/10.1007/s12094-021-02762-y

Pediatric medulloblastoma express immune checkpoint B7-H3. / Li, S; Poolen, G C; van Vliet, L C et al.
In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, Vol. 24, No. 6, 06.2022, p. 1204-1208.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Pediatric medulloblastoma express immune checkpoint B7-H3

AU - Li, S

AU - Poolen, G C

AU - van Vliet, L C

AU - Schipper, J G

AU - Broekhuizen, R

AU - Monnikhof, M

AU - Van Hecke, W

AU - Vermeulen, J F

AU - Bovenschen, N

N1 - Funding Information: This work was supported by a research grants from Cancer Foundation Koppie-Au and Foundation Team Doelbewust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2022, The Author(s).

PY - 2022/6

Y1 - 2022/6

N2 - PURPOSE: Medulloblastomas (MB) are highly malignant brain tumors that predominantly occur in young infants. Immunotherapy to boost the immune system is emerging as a novel promising approach, but is often hampered by inhibitory immune checkpoints. In the present study, we have studied immune checkpoint B7-H3 expression in a tissue cohort of human pediatric MB.METHODS: Expression of B7-H3 was detected by immunohistochemistry and classified via B7-H3 staining intensity and percentage of B7-H3 positive tumor cells. Subsequently, B7-H3 protein expression was distinguished in MB molecular subtypes and correlated to immune cell infiltrates, patient characteristics, and survival.RESULTS: B7-H3 protein expression was found in 23 out of 24 (96%) human pediatric MB cases and in 17 out of 24 (71%) MB cases > 25% of tumor cells had any level of B7-H3 expression. B7-H3 protein expression was more frequent on Group-4 MB as compared with other molecular subtypes (p = 0.02). Tumors with high B7-H3 expression showed less influx of γδT cells (p = 0.002) and CD3+ T cells (p = 0.041).CONCLUSION: Immune checkpoint B7-H3 is differentially expressed by the large majority of pediatric MB. This further warrants the development of novel B7-H3-directed (immuno)therapeutic methods for children with incurable, metastatic, or chemo-resistant MB.

AB - PURPOSE: Medulloblastomas (MB) are highly malignant brain tumors that predominantly occur in young infants. Immunotherapy to boost the immune system is emerging as a novel promising approach, but is often hampered by inhibitory immune checkpoints. In the present study, we have studied immune checkpoint B7-H3 expression in a tissue cohort of human pediatric MB.METHODS: Expression of B7-H3 was detected by immunohistochemistry and classified via B7-H3 staining intensity and percentage of B7-H3 positive tumor cells. Subsequently, B7-H3 protein expression was distinguished in MB molecular subtypes and correlated to immune cell infiltrates, patient characteristics, and survival.RESULTS: B7-H3 protein expression was found in 23 out of 24 (96%) human pediatric MB cases and in 17 out of 24 (71%) MB cases > 25% of tumor cells had any level of B7-H3 expression. B7-H3 protein expression was more frequent on Group-4 MB as compared with other molecular subtypes (p = 0.02). Tumors with high B7-H3 expression showed less influx of γδT cells (p = 0.002) and CD3+ T cells (p = 0.041).CONCLUSION: Immune checkpoint B7-H3 is differentially expressed by the large majority of pediatric MB. This further warrants the development of novel B7-H3-directed (immuno)therapeutic methods for children with incurable, metastatic, or chemo-resistant MB.

KW - Brain cancer

KW - Immune checkpoint

KW - Immunotherapy

KW - Pediatric medulloblastoma

UR - https://www.scopus.com/pages/publications/85122280872

U2 - 10.1007/s12094-021-02762-y

DO - 10.1007/s12094-021-02762-y

M3 - Article

C2 - 34988920

SN - 1699-048X

VL - 24

SP - 1204

EP - 1208

JO - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

JF - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

IS - 6

ER -

Pediatric medulloblastoma express immune checkpoint B7-H3

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this